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Abstract
Background: Obesity is one of the most prevalent health problems in the canine population. While haemostatic
parameters and markers of endothelial function have been evaluated in various disease conditions in dogs, there
are no studies of these markers in canine obesity. This study was designed to evaluate the effect of naturally gained
weight excess and obesity on inflammatory, hemostatic and endothelial biomarkers in dogs. A total of 37 overweight
and obese dogs were compared with 28 normal weight dogs.
Results: Overweight and obese dogs had significantly elevated concentrations of serum interleukin-6 (IL-6) and
C-reactive protein (hsCRP). Number of platelets, activity of factor X and factor VII were significantly higher, while
activated partial thromboplastine time (aPTT) and soluble plasminogen activator receptor (suPAR) were significantly
decreased. Statistical analysis of high mobility group box – 1 protein (HMGB-1), soluble intercellular adhesive molecule -1
(sICAM-1) and plasminogen activator inhibitor type 1 (PAI-1) concentrations did not show significant differences
between the total overweight and obese group and the normal weight group of dogs.
Conclusions: Analytical changes in the dogs in our study reflects that weight excess in dogs can be associated
with a chronic low degree of inflammation and a hypercoagulable state, where primary and secondary hemostasis are
both affected. However obesity is not associated with impairment of endothelial function in dogs.
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Background
Obesity is a widespread health problem in dogs living in
developed countries. The incidence of canine obesity is
increasing in parallel with human obesity [1]. Current
estimates indicate that more than 30% of dogs are over-
weight or obese, and canine obesity should be a serious
concern both for veterinarians as well as for pet owners
due to the high number of diseases that can be associated
with this condition [1–3].
Although there are controversial results for dogs, a link
between obesity and inflammation has been established in
human obesity, and increases in interleukin-6 (IL-6) in
obese humans were observed [4, 5]. Interleukin -6 is a
pleiotropic cytokine with a wide range of biological activi-
ties in immune regulation, inflammation, and whole-body
energy homeostasis [6–8]. One of the main effects of IL-6
is activation of hepatocytic receptors, resulting in in-
creased synthesis of certain proteins [9]. This includes
induction of hepatic C-reactive protein (CRP) and fibrino-
gen (FIB) production, which are known to be acute phase
proteins in dogs [10] and major risk markers of cardiovas-
cular complications in humans [11].
Inflammation and coagulation are closely linked, both
in health and disease, and share common activation and
regulation systems [12]. Various mediators that induce a
chronic inflammatory state in obesity are closely con-
nected with haemostatic disturbances and recent studies
have shown that the obesity state is characterised by
prothrombotic state in humans [13–15], rodents [16],
cats [17] and pigs [18]. Obesity induces alterations of
both intrinsic and extrinsic pathways increasing the
activities of vitamin K-dependent clotting factors [15].
There is also evidences that primary hemostasis is
affected by weight excess, characterised by increased
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platelet number in circulation in humans [14] and dogs
[19]. In addition, impaired fibrinolysis due to increased con-
centrations of plasminogen activator inhibitor-1 (PAI-1),
and the soluble form of plasminogen activator receptor
(suPAR) could occur as a consequence of weight excess
[20, 21]. While the mechanisms linking human obesity with
prothrombotic changes, including upregulation of pro-
coagulant factors, downregulation of anticoagulants and
inhibition of fibrinolysis are beginning to be understood
and explained [13, 15], haemostatic balance in canine over-
weight/obesity conditions remains uninvestigated.
Endothelial dysfunction is a complication described in
human obesity and other species including mice [22, 23].
Disturbances in endothelial function can be assessed by
two serum biomarkers, high mobility group box – 1 pro-
tein (HMGB – 1) and intercellular adhesive molecule -1
(ICAM - 1) [24, 25]. Fiuza et al. [26] demonstrated that
HMGB-1 induces a proinflammatory change in human
microvascular endothelial cells in vitro, being considered
as a marker of endothelial function. ICAM -1 is also
considered as a marker of endothelial activation [25] and
is elevated in a broad array of disease states, including
obesity [25]. Both biomarkers are increased in human
obesity and are also related, since HMGB-1 induces a pro-
inflammatory change in human microvascular endothelial
cells in vitro, characterized by up-regulation of ICAM-1
and production of proinflammatory cytokines [26].
Haemostatic parameters and markers of endothelial
function have been evaluated in numerous disease con-
ditions in humans and mices, including obesity [25, 27],
although there are no studies of these markers in canine
weight excess. The aim of the present study was to estab-
lish whether naturally gained canine weight excess could
produce changes in primary and secondary haemostasis as
well as in markers of endothelial function.
Methods
Study population
This was a prospective study in which two groups were
established: lean dogs and overweight and obese dogs.
Clients from the University Veterinary Hospital were
contacted and were asked whether they had dogs that
would fulfill the criteria of admission to the study that
consisted of being free of illness, and of vaccination or
medication administration within 2 months prior to
sample collection. In case of overweight and obese dogs,
they should have been in this state for at least one year
and not participated in a weight-loss program at the
time of enrolment. If the dog fullfilled the inclusion cri-
teria, its owner was asked to bring the dog to the hospital
for a systematic examination, which included detailed
clinical inspection and routine hematological and bio-
chemical analysis.
All lean dogs (n = 28) were deemed healthy based on a
detailed normal history, clinical inspection, hematological
and biochemical laboratory results and that were all in the
reference range. Mixed different breeds were represented.
The lean group was matched in age and sex to the group
of dogs with weight excess.
Each owner of overweight and obese (n = 41) dogs was
questioned about the duration of weight excess. Various
breeds were represented. The overweight and obese
group of dogs consisted of 10 crossbreeds, 7 golden re-
trievers, 7 labradors, 2 pekingese, 2 belgian shepherds, 2
beagles, 1 bernese mountain dog, 1 pug-dog, 1 tornjak, 1
dalmatian dog, 1 great dane, 1 mexican hairless dog
and 1 stafford. The normal weight group of dogs con-
sisted of 7 crossbreeds, 6 golden retrievers, 4 labradors
and 10 mixed breeds. In four overweight and obese
dogs we determined two metabolic underlying condi-
tions that could have been related to weight excess -
hypothyroidism (2 dogs) and diabetes mellitus (2 dogs).
These dogs were excluded from the study, so the total
number of overweight and obese dogs was 37. The
assessment of the nutritional condition was based on a
5-point body condition scoring (BCS) system [28]. A
single investigator assigned the dog to either lean (BCS 3),
overweight (BCS 4) or obese (BCS 5). In addition, the
weight of the dogs was compared with the standard
weight for the breed. The weight of overweight dogs
was 15 – 30% above ideal and the weight of obese dogs
was > 30% above ideal [29] Table 1.
Basic hematological and biochemical parameters of
two groups of the dogs are shown in Table 2.
Laboratory measurements
The dog owners were asked to fast their dogs for 12 h
prior to presentation for blood sampling. A sample of
6 ml of peripheral venous blood was drawn into EDTA or
citrate tubes (Becton Dickinson, Rutherford, NJ, USA).
Plasma was separated from blood cells by centrifugation
at 1200 g for 15 min. Two 0.5 ml aliquots of EDTA and
citrate plasma were separated and transferred to -80 °C
within 1 h of collection and stored until analysis. The
hematological, biochemical and hormonal analysis were
performed immediately after the venipuncture.
Table 1 Characterization of the study population
Normal weight Overweight and obese
Number of dogs 28 37
Number of males and
females (%)
40, 60 40, 60
Neutered/spayed 3 4
Age (years, range) 6.5 (2–14) 7.5 (2–15)
Weight excess (%, range) 0 28 (15–54)
Body condition score 3 4 and 5
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Fibrinogen concentration, clotting factor activity, pro-
thrombine time (PT) and activated partial thrombo-
plastine time (aPTT) were measured in citrate plasma
by a coagulometric method, using ACL 7000 analyser
(Instrumentation Laboratory, Bedford, USA) based on a
canine calibration curve with original reagents from the
manufacturer. We used a coagulometric assay with spe-
cific factor-depleted plasma to assess the biological ac-
tivity of the measured clotting factors. The clotting
factors FVII, FIX and FX were measured by procoagu-
lant activity as F VII:C, F IX:C and F X:C in a coagula-
tion end point assay using specific factor – depleted
plasma, having less than 1% activity for the specific fac-
tor being measured and close to 100% activity of all
other factors. The activity of the factors was determined
relative to a canine pool of samples obtained from
healthy animals and expressed as %. The calibration
curve was made using the citrate plasma pool obtained
from healthy animals. The intraassay coefficient of vari-
ation was less than 4%, while interassay precision was
less than 7%.
Prothrombin time is dependent on the functional ac-
tivity of clotting factors FVII, FX, FV, FII and fibrinogen.
Platelet poor plasma was mixed with tissue factor at
37 °C and an excess of calcium chloride was added to
initiate coagulation. The time taken from the addition
of calcium to the formation of the fibrin clot is known
as the PT. The aPTT measures the activity of the in-
trinsic and common pathways of coagulation. Platelet
poor plasma was incubated at 37 °C and phospholipid
and a contact activator were added followed by calcium.
The aPTT is the time taken from the addition of calcium
to the formation of a fibrin clot, expressed in seconds.
The number of platelets (PLT) and their mean volu-
men (MPV) were evaluated using an automatic blood
cell counter "Horiba ABX" (Diagnostics, Montpellier,
France) and original manufacturer's reagents.
High mobility group box – 1, sICAM-1, hsCRP, IL-6,
PAI-1 and suPAR were determined using ELISA kits
specific for canine samples manufactured by Biotang
(Biotang Source International, Camarillo, USA) following
the manufacturer's instructions. All of the measurements
were performed at the same time in order to avoid pro-
cedural variations. All the species specific ELISA kits used
had a similar basis. Purified canine specific antibodies
against the analyte to be measured were pre-coated onto a
microplate. The standards, controls and samples were
added into the wells. After washing away any unbound
substances, a HRP-labeled antibody was added to form
a complex of antibody-antigen-enzyme labeled anti-
body. After a second washing to remove any unbound
antibody- enzyme reagent, tetramethylbenzidine sub-
strate was added, producing a blue color when catalyze
by the HRP enzyme. The reaction was terminated by
addition of a stop solution that changes the solution
color from blue to yellow. Optical density was mea-
sured with a microplate reader at 450 nm (BioTek
Instruments, Vermont, USA). A standard curve, pre-
pared from five standard dilutions in duplicate, was
used for calculating the concentration of analyte in the
canine samples, expressed in μg/ml, ng/ml or pg/ml.
The intraassay coefficients of variation were less than
Table 2 Basic hematological and biochemical parameters in normal weight and overweight/obese dogs
Group RBC RDW MCV MCH MCHC HB HTC
(x1012/L) (fl) (pg) (g/l) (g/l) (%)
N 6.0 5.3–8.5 14 11–16 72 65–77 23 20–26 328 309–369 162 135–193 49 38–58
O 7.0 5.5–9.2 14 11–16 71 60–76 23 21–31 329 179–457 170 121–233 50 37–62
Ref. 5.5–8.5 11–16 60–77 19–23 320–360 120–180 37–55
WBC NEU MO LY EO NS Ba
(x109/L) (%) (%) (%) (%) (%) (%)
N 9.4 5.4–17.4 60 39–77 1 0–8 34 17–55 4 0–18 0 0–1 0 0
O 9.1 3.9–13.5 67 22–91 1 0–10 24* 5–71 3 0–23 0 0–1 0 0
Ref. 6–17 60–70 3–10 12–33 2–10 0–1 0–1
BUN CRE BIL GLUK AST ALT YGT
(mmol/l) (μmol/l) (μmol/l) (mmol/l) (IU/l,37 °C) (IU/l,37 °C) (IU/l,37 °C)
N 6.5 3.7–9.5 100 81–128 3.6 1.5–9.4 4.5 2.7–5.9 31 19–60 47 25–142 3 1–9
O 4.7* 3–12 93* 20–129 3.4 1.5–10.4 5.0 3.5–6.0 32 19–62 42 22–187 3 1–6
Ref. 3.3–8,3 44–140 1.7–8.6 3.6–6.5 −82 −88 −6
RBC red blood cells, RDW red distribution width, MCV mean cell volume, MCH mean cellular hemoglobin, MCHC mean cellular hemoglobin concentration,
HB hemoglobin concentration, HTC hematocrit, WBC total leukocyte count, NEU segmented neutrophils, MO monocytes, LY lymphocytes, EO eosinophils,
NS nonsegmented neutrophils, Ba basophils, BUN blood urea nitrogen, CRE creatinine, GLUC glucose, BIL total bilirubin, AST aspartate aminotransferase,
ALT alanine aminotransferase, YGT gamma glutamyl transferase, N control normal weight dogs (N = 28), O total overweight and obese dogs (N = 37), median,
minimum and maximum is shown, ref. reference range in our laboratory, *p ≤ 0.05
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10%, and the interassay coefficients of variation were
less than 12% for all measured analytes. The lower limit
of assay detection was 6 ng/ml for HMGB-1, 1.25 μg/ml
for sICAM-1, 16 pg/ml for IL-6, 0.30 μg/ml for hsCRP,
2 ng/ml for PAI-a and 20 pg/ml for suPAR.
Statistical analysis
Distribution of all variables was tested by the Kolmogorov-
Smirnov test. Analytes with a normal distribution were
expressed as mean and SD and analytes with non-normal
distribution by median and the 25th and 75th percentile.
Differences between lean and weight excess dogs were
tested by either t test or Mann–Whitney U test. Multiple
linear regression analysis was performed to evaluate corre-
lations between analytes in normalweight and overweight/
obese dogs. Statistical analyses were performed with com-
puter software (Statistica for Windows, StatSoft Inc.), with
the level of significance set at p < 0.05.
Ethical approval
The study protocol was approved by the Ethics Committee
for Animal Experimentation, Faculty of Veterinary Medi-
cine, University of Zagreb, Croatia. All dog owners gave
written informed consent before entering the study. The
study complied with local and international laws for the
use of animals in clinical research.
Results
All lean, overweight and obese dogs had concentrations
of plasma HMGB-1, sICAM-1, IL-6, hsCRP, PAI-1 and
suPAR in the range of the ELISA assay detection.
Overweight and obese dogs had significantly elevated
IL-6 and hsCRP compared with normal weight dogs
(261 pg/ml vs. 227 pg/ml, p = 0.001 for IL-6; 4.2 μg/ml
vs. 3.7 μg/ml, p = 0.027 for hsCRP).
When hemostatic variables were studied, overweight
and obese dogs showed significantly higher values of
average PLT number, activity of factor X and factor VII
(315x109/L vs. 234 x109/L, p = 0.001 for PLT; 115% vs.
104%, p = 0.007 for FX, 131% vs 109%, p = 0.054 for
FVII) and significantly lower values of aPTT and suPAR
compared with lean dogs (10 s vs. 11 s, p = 0.022 for
aPTT, 1990 pg/ml vs. 2598 pg/ml, p = 0.002 for suPAR).
Statistical analysis of HMGB-1, sICAM-1, PAI-1 con-
centrations and MPV did not show significant differences
between the total overweight and obese group and the
lean dogs (Tables 2 and 3).
A significant positive correlation was found for IL-6
and HMGB-1 (p < 0.05, r = 0.62), and for FX and FIX
(p < 0.05, r = 0.48), while a significant negative correl-
ation was found for aPTT and FIX (p < 0.05, r = -0.51).
Discussion
The connection between weight excess and inflammation,
haemostasis and endothelial disturbances has mostly been
explored in humans, as well as in mouse and rat models,
while similar investigations are in their early stages in
canine medicine.
Biomarkers of inflammation, IL-6 and hsCRP were in-
creased in overweight and obese dogs (p = 0.001; p = 0.027).
Although no changes in these inflammatory biomarkers
have been detected after short-term experimentally in-
duced obesity or weight loss [30], and some authors even
reported decreased CRP in obese dogs [31], our results
would be more in line with those obtained by German et
al. [32], for obese dogs in a clinical setting. These values
could reflect a chronic low degree of inflammation or even
that relatively minor changes in CRP under reference
ranges could reflect genetic, demographic, behavioural or
dietary factors [33]. The primary source of circulating IL-6
in obesity could be macrophages that have infiltrated
white adipose tissue and accumulated during obesity due
to local hypoxia. One of the main effects of IL-6 is the in-
duction of hepatic CRP and FIB production, playing a key
role in the inflammatory processes associated with obesity
[34, 35]. In addition, there is evidence that CRP is pro-
duced in the adipose tissue itself [36], so in addition to in-
creased hepatic production, proliferating adipose tissue
could also represent a source of this acute-phase marker
in overweight and obese dogs.
Weight excess in dogs shifts the hemostatic balance
and features a hypercoagulable state, which is charac-
terised by increased activity of FX (p = 0.007) and FVII
(p = 0.054), shortened aPTT (p = 0.022) and increased
number of PLT in circulation (p = 0.001). Similar results
indicating increased activity of vitamin K-dependent
clotting factors were found in obesity in humans [37]
and mices [38]. A connection between body fat content
and altered haemostasis is also found in pigs [39]. An
explanation could be increased liver production of clot-
ting factor as a consequence of a chronic inflammatory
state, but Cleuren et al. [38] found that in obesity the
factors activity in plasma was not paralleled by changes
in transcription levels in the liver. Moreover, Takahashi
et al. [40] found that obese adipose tissue itself produced
FVII, and that the production and secretion of FVII by
adipocytes was enhanced by proinflammatory cytokines,
so the possible role of chronic inflammatory state on
canine adipocytes as an alternative source of some clot-
ting factors remains to be investigated. A significantly
shorter aPTT has been found in obese rats [16],
humans [41] and mices [38], which is in line with our
results. The clinical significance of short aPTT in diag-
nostics has recently gained interest, because aPTT
might be usefull as a widely available and inexpensive
marker of hypercoagulability [41].
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The primary haemostasis in dogs with weight excess
was affected due to increased platelet count, while the
mean platelet volume remained unchanged compared
with normal lean dogs. Similar findings have been found
in obese dogs [19], pigs [18] and children [42]. Cytokine
IL-6 was found to acts as a promotor of the maturation
of megakaryocyte precursors, and this prothrombotic
effect may explain the association between the increased
markers of chronic inflammation and the elevated platelet
count in obese humans [43], and possibly also in dogs.
In spite of the fact that obesity is characterized by
decreased fibrinolysis in humans [13] where PAI-1 rep-
resents a part of the fibrinolytic system that is most dis-
ordered, in our experiments we did not find any changes
in the PAI-1 concentration. In addition the soluble form
of urokinase PAR, suPAR, was decreased in dogs with
weight excess (p = 0.002). These findings disagree with
other authors that investigated the effect of human obes-
ity on the fibrinolytic system, where increased levels of
suPAR was found [44, 45]. Further studies should be
performed to determine the reason for these divergences
in the behaviour of suPAR in canine and human obesity.
Proteins belonging to the HMGB-1 goup did not show
a significant increase in dogs with weight excess. These
proteins have been reported to increase in dogs with
acute inflammation and neoplasms [46–49]. In our study
we used species-specific canine antibodies and a highly
sensitive assay for HMGB-1 that allowed us to quantify
this protein in healthy control dogs, in contrast to other
studies that reported no detectable concentration using
assays designed for humans [47]. Our findings suggest
that overweight condition and obesity are not associated
with greater impairment of endothelial function in
dogs. Similarly, HMGB-1 and sICAM-1 did not show
significant increases in obese dogs in our study, con-
trary to what has been described in humans [50, 51].
One of the risk factors for atherosclerosis is an increase
of sICAM-1. Therefore, the lack of increase of this pro-
tein in obese dogs could be related to the low frequency
of atherosclerosis found in this species compared with
humans, where it is a leading cause of mortality and is
responsible for much of the morbidity [52].
Interleukin -6 was positively correlated with HMGB-1.
A similar relationship between these two proteins was
found by Zeng et al. [53] in human infectious disease.
Moreover, Nativel et al. [54] concluded that HMGB-1 is
an adipokine, which stimulates IL-6 secretion and may
contribute to chronic inflammation in fat tissue of
humans. Our finding suggest that HMGB-1 may play a
role in the chronic inflammatory state in dogs.
The main study limitation was that client-owned ani-
mals living in a home environment were used, which
contributed to study variability, where diet, exercise and
husbandry were variable. In addition, we did not have
the opportunity to follow the effect of weight loss on the
measured biomarkers. Despite these limitations, this
study provides a comprehensive analysis of proinflam-
matory events, haemostasis and endothelial function
Table 3 Values of the inflammatory, hemostatic and endothelial biomarkers measured in this study in normal weight and
overweight/obese dogs
Parameter/unit Normal weight Dogs Overweight And obese dogs R and P -value
Mean ± SEM Median; CI (P 25–P 75) Mean ± SEM Median; CI (P 25–P 75)
sICAM-1 μg/ml 320 ±13 321; 275–356 329 ± 8.2 326; 288–361 9.021; pd 0.536
IL–6 pg/ml 227 ± 8.9 220; 197–256 261 ± 4.9 259; 235–287 34.829; pd 0.001 **
HMGB-1 ng/ml 85 ± 4.5 83; 70–93 89 ± 2.6 89; 76–98 4.343; pd 0.384
hsCRP μg/ml 3.7 ± 0.17 3.7; 3.2–4.3 4.2 ± 0.14 3.9; 3.6–4.7 0.502; pd 0.027 *
suPAR pg/ml 2598 ± 136 2559; 2195–2923 1990 ± 126 1869; 1542–2486 −608.314; pd 0.002 *
PAI-1 ng/ml 70 ± 5.9 61; 44–94 75 ± 6.9 70; 43–86 1.145; np 0.611
FIB g/L 2.6 ± 0.16 2.6; 2.0–3.0 3.0 ± 0.20 2.6; 2.2–3.5 1.312; np 0.185
FIX % 96 ± 5.6 93; 77–106 112 ± 6.8 100; 84–140 1.385; np 0.081
FVII % 109 ± 6.2 110; 82–136 131 ± 8.7 125; 100–147 1.492; pd 0.054 *
FX % 104 ± 2.2 106; 94–112 115 ± 2.9 110; 102–128 11.557; pd 0.007 **
PT sec 6.1 ± 0.04 6.1; 6.0–6.2 6.1 ± 0.04 6.1 6.0–6.2 0.989; np 0.580
aPTT sec 11 ± 0.23 11; 10–12 10 ± 0.20 10; 9.3–11 −0.749; pd 0.022 *
MPV fl 8.3 ± 0.14 8; 8–9 8.6 ± 0.17 8; 8–9 0.318; pd 0.169
PLT x109/L 234 ± 13 228; 201–265 315 ± 18 298; 253–401 80.916; pd 0.001 **
HMGB-1 high mobility group box – 1 protein, sICAM-1 soluble intercellular adhesive molecule -1, IL-6 interleukin – 6, hsCRP high sensitivity C reactive protein, PAI-1
plasminogen activator inhibitor type 1, suPAR soluble plasminogen activator receptor, FIB fibrinogen, FX, FIX, FVII clotting factors X, IX and VII, PT prothrombine
time, aPTT activated partial thromboplastine time, MPV mean platelet volume, PLT number of platelets, np nonparametric distribution, pd parametric distribution
*p ≤ 0.05, **p < 0.01,
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associated with weight excess in dogs. Further studies
should be made in the future with a larger population of
dogs to confirm these findings and in addition it would
be interesting to compare in obese dogs whether the ex-
istence of obesity related metabolic symdrome (ORMD)
could alter these analytes.
Conclusions
In this report we showed that weight excess in dogs
potentiates the prothrombotic state in apparently healthy
animals. This could at least in part, be due to a chronic
proinflammatory state. Altered haemostasis may be rele-
vant as a pathological contributor to other haemostatic
diseases if dog is overweight or obese. The fibrinolytic sys-
tem in canine obesity and the role of decreased suPAR is
not yet clear and needs to be further investigated. The
positive correlation of IL-6 with HMGB-1 suggests that
HMGB-1 could also have a role in the chronic inflamma-
tory state in dogs.
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